Nezebi (Oxymetazoline Hydrochloride)

Oxymetazoline is a selective alpha‑1 and alpha‑2 adrenergic receptor agonist. By stimulating these receptors on nasal blood vessels, it causes vasoconstriction, which decreases mucosal edema and opens the nasal airway, providing rapid decongestion.

The appropriate dose of Nezebi is determined by a qualified healthcare professional. For most OTC products, the typical recommendation is one or two sprays per nostril every 10 to 12 hours, not exceeding three days of continuous use, but exact dosing should follow the prescriber's instructions.

Safety data for oxymetazoline in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should consult their healthcare provider before using Nezebi to weigh potential benefits against any unknown risks.

To order Nezebi, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nezebi (oxymetazoline) provides rapid, localized vasoconstriction and typically lasts longer than phenylephrine, another OTC decongestant. However, both share similar safety considerations, such as the risk of rebound congestion if used beyond three days. Choice of agent often depends on individual response and physician preference.

Nezebi should be stored at room temperature, away from excess heat and direct sunlight. Keep the product in its original packaging to protect it from moisture and ensure the spray mechanism remains functional.

Nezebi is applied as a nasal spray. The user gently inserts the nozzle into each nostril, tilts the head slightly forward, and delivers the prescribed number of sprays. The spray should be directed toward the outer wall of the nostril, not the nasal septum, to minimize irritation.

Serious risks include rebound nasal congestion with prolonged use, significant elevation of blood pressure, and cardiac arrhythmias. If any signs of hypertension, rapid heartbeat, severe headache, or worsening nasal symptoms occur, discontinue use and seek medical attention promptly.

Nezebi should not be used by children under six years of age, individuals with known hypersensitivity to oxymetazoline or any formulation components, and patients with severe hypertension, coronary artery disease, or uncontrolled cardiovascular conditions unless directed by a physician.